Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL versus BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL versus BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER.
ATENOLOL vs BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
50 mg orally once daily; may increase to 100 mg orally once daily if needed.
Intravenous: For stable patients, an initial loading dose of 500 mcg/kg/min over 1 minute followed by a maintenance infusion of 50 mcg/kg/min for 4 minutes; if response is inadequate, increase maintenance infusion to 100 mcg/kg/min and repeat loading dose after 10 minutes. Titrate in 50 mcg/kg/min increments up to 200 mcg/kg/min. For intraoperative and postoperative use, see full prescribing information.
None Documented
None Documented
Clinical Note
moderateAtenolol + Digoxin
"Atenolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateAtenolol + Digitoxin
"Atenolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateAtenolol + Deslanoside
"Atenolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateAtenolol + Acetyldigitoxin
"Atenolol may increase the bradycardic activities of Acetyldigitoxin."
6-9 hours (terminal elimination half-life); may increase to 15-30 hours in renal impairment (CrCl <35 mL/min).
Terminal elimination half-life is approximately 9 minutes (range 8–10 minutes). Clinically, the half-life is consistent with rapid offset of effect upon discontinuation; steady state is achieved within 30 minutes of continuous infusion.
Renal: 40-50% unchanged drug; minor hepatic metabolism (10-20%) with biliary excretion of metabolites; <5% fecal.
Primarily metabolized by red blood cell esterases; <1% excreted unchanged in urine. Elimination is not dependent on renal or hepatic function.
Category C
Category C
Beta-Blocker
Beta-Blocker